tiprankstipranks
Trending News
More News >
Immutep (IMMP)
NASDAQ:IMMP

Immutep (IMMP) AI Stock Analysis

Compare
668 Followers

Top Page

IM

Immutep

(NASDAQ:IMMP)

Rating:50Neutral
Price Target:
$2.00
▲(7.53%Upside)
The overall stock score of 50 reflects Immutep's financial challenges typical of R&D-intensive biotechnology firms. While the balance sheet is stable, consistent losses and cash flow issues weigh heavily. Technical analysis suggests some potential for momentum, but valuation remains a concern due to the negative P/E ratio and lack of dividends.
Positive Factors
Clinical Trial Results
Immutep reported positive response data from the ongoing P1 INSIGHT-003 study evaluating the triple combination of eftilagimod + chemotherapy + Keytruda in 1L metastatic non-small cell lung cancer, demonstrating a 60.8% overall response rate and 90.2% disease control rate.
Financial Position
The company has a strong cash position, expecting to be funded through the end of 2026.
Regulatory Progress
Immutep has requested a meeting with the FDA to discuss the path forward, indicating progress in regulatory engagement.
Negative Factors
Historical Controls
In the TPS <50% subgroup, the triple combo demonstrated a 59.6% overall response rate vs. 40.8% for historical control.
Survival Data
Survival data from the INSIGHT-003 study showed a median overall survival of 32.9 months and a 24-month overall survival rate of 81.0%.
Treatment Comparison
The combination therapy of efti + Keytruda has demonstrated a progression-free survival of 5.8 months and a median duration of response of 9.3 months.

Immutep (IMMP) vs. SPDR S&P 500 ETF (SPY)

Immutep Business Overview & Revenue Model

Company DescriptionImmutep (IMMP) is a biotechnology company specializing in the development of immunotherapeutic products for cancer and autoimmune diseases. The company is primarily focused on leveraging its expertise in LAG-3 (Lymphocyte Activation Gene-3) to develop innovative therapies that enhance the body's immune response. Immutep's core products include eftilagimod alpha, a soluble LAG-3 protein, and IMP761, an early-stage product aimed at autoimmune diseases.
How the Company Makes MoneyImmutep makes money through the development and commercialization of its proprietary immunotherapy products. The company's primary revenue streams include licensing agreements, milestone payments, and royalties from partnerships with major pharmaceutical companies. Immutep collaborates with industry leaders to advance its products through clinical trials, which can result in upfront payments and subsequent financial compensation upon achieving specific development or sales milestones. Additionally, Immutep may receive funding and grants to support its research and development activities, contributing to its overall earnings.

Immutep Financial Statement Overview

Summary
Immutep's financials reflect typical challenges faced by biotechnology firms in the development phase. While the income statement shows ongoing losses and negative margins, the balance sheet remains stable with strong equity and low leverage. Cash flow challenges persist, primarily due to high R&D expenditure, but are mitigated by substantial financing efforts. The company’s financial health is contingent on its ability to continue securing funding and ultimately achieving successful product commercialization.
Income Statement
42
Neutral
Immutep displays a challenging income statement with a negative gross profit margin and consistently negative net income. Revenue growth has been volatile, with recent growth from a low base. The EBIT and EBITDA margins are deeply negative, reflecting ongoing operational and structural challenges. The company’s financial trajectory indicates difficulty in achieving profitability in the near term, common in biotechs during extensive R&D phases.
Balance Sheet
58
Neutral
The balance sheet shows a strong equity position with low debt levels, resulting in a favorable debt-to-equity ratio. The equity ratio is robust, highlighting financial stability and a solid asset base. However, the continuous losses and cash burn could pressure equity if not offset by ongoing financing activities, a typical scenario in the biotechnology sector.
Cash Flow
50
Neutral
Cash flow analysis reveals negative operating and free cash flows as expected in an R&D-intensive biotech firm. Operating cash flow to net income ratio is not favorable, indicating significant cash burn relative to revenue generation. Free cash flow remains negative, but the company has managed significant financing to support operations, a critical factor for sustaining R&D activities.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
4.88M3.84M3.51M170.37K3.97M7.49M
Gross Profit
-41.56M-37.70M1.44M-1.89M1.90M-14.99M
EBIT
-96.29M-88.10M-44.94M-33.94M-19.56M-16.02M
EBITDA
-48.74M-44.54M-39.57M-31.87M-17.77M-13.46M
Net Income Common Stockholders
-43.87M-42.72M-39.90M-32.21M-29.90M-13.47M
Balance SheetCash, Cash Equivalents and Short-Term Investments
54.88M181.88M123.42M80.00M60.13M26.32M
Total Assets
76.47M201.58M147.45M102.17M82.03M46.60M
Total Debt
9.75M1.59M1.23M1.73M2.82M9.05M
Net Debt
-45.13M-160.20M-122.19M-78.26M-57.31M-17.27M
Total Liabilities
15.78M12.06M10.98M8.09M8.76M13.30M
Stockholders Equity
60.69M189.52M136.47M94.08M73.27M33.30M
Cash FlowFree Cash Flow
-46.43M-35.75M-35.93M-30.25M-17.66M-10.86M
Operating Cash Flow
-45.96M-34.82M-35.88M-30.23M-17.64M-10.84M
Investing Cash Flow
-73.32M-21.02M-31.00K-22.91K-15.60K-19.35K
Financing Cash Flow
95.24M95.18M76.04M50.33M52.68M20.48M

Immutep Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.86
Price Trends
50DMA
1.77
Positive
100DMA
1.84
Positive
200DMA
1.98
Negative
Market Momentum
MACD
<0.01
Positive
RSI
49.53
Neutral
STOCH
12.54
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMP, the sentiment is Neutral. The current price of 1.86 is below the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.77, and below the 200-day MA of 1.98, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.53 is Neutral, neither overbought nor oversold. The STOCH value of 12.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMMP.

Immutep Risk Analysis

Immutep disclosed 52 risk factors in its most recent earnings report. Immutep reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. Q2, 2024

Immutep Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$345.71M-41.31%-7.93%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
50
Neutral
$256.18M-31.16%15.14%
47
Neutral
$272.14M-30.47%-22.66%
44
Neutral
$338.04M-32.89%27.92%
44
Neutral
$238.64M-29.93%3.38%-36.40%
41
Neutral
$389.24M-23.68%14.60%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMMP
Immutep
1.86
-0.78
-29.55%
ATXS
Astria Therapeutics
5.99
-3.15
-34.46%
YMAB
Y-Mabs Therapeutics
5.27
-6.80
-56.34%
ITOS
iTeos Therapeutics
10.17
-6.41
-38.66%
AVIR
Atea Pharmaceuticals
3.18
-0.61
-16.09%
CMPX
Compass Therapeutics
2.50
1.29
106.61%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.